ATE423852T1 - Methoden zur diagnose und prognose von krebs - Google Patents

Methoden zur diagnose und prognose von krebs

Info

Publication number
ATE423852T1
ATE423852T1 AT97920115T AT97920115T ATE423852T1 AT E423852 T1 ATE423852 T1 AT E423852T1 AT 97920115 T AT97920115 T AT 97920115T AT 97920115 T AT97920115 T AT 97920115T AT E423852 T1 ATE423852 T1 AT E423852T1
Authority
AT
Austria
Prior art keywords
cancer
methods
prb2
mutations
predict
Prior art date
Application number
AT97920115T
Other languages
English (en)
Inventor
Antonio Giordano
Alfonso Baldi
Original Assignee
Antonio Giordano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antonio Giordano filed Critical Antonio Giordano
Application granted granted Critical
Publication of ATE423852T1 publication Critical patent/ATE423852T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97920115T 1996-04-05 1997-04-03 Methoden zur diagnose und prognose von krebs ATE423852T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1494396P 1996-04-05 1996-04-05
US1937296P 1996-06-05 1996-06-05
US2019696P 1996-06-21 1996-06-21
US3953297P 1997-03-03 1997-03-03

Publications (1)

Publication Number Publication Date
ATE423852T1 true ATE423852T1 (de) 2009-03-15

Family

ID=27486431

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97920115T ATE423852T1 (de) 1996-04-05 1997-04-03 Methoden zur diagnose und prognose von krebs

Country Status (7)

Country Link
EP (2) EP0906448B1 (de)
JP (2) JP2000510330A (de)
AT (1) ATE423852T1 (de)
AU (1) AU2438997A (de)
CA (1) CA2250854C (de)
DE (1) DE69739276D1 (de)
WO (1) WO1997038125A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2292378C (en) * 1997-06-02 2011-01-25 Thomas Jefferson University A method of inhibiting cancer cell growth using a vector expressing prb2/p130
ATE413466T1 (de) * 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US6261778B1 (en) * 1998-10-22 2001-07-17 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode SCP proteins, and uses thereof
US20020051990A1 (en) * 2000-06-09 2002-05-02 Eric Ople Novel gene targets and ligands that bind thereto for treatment and diagnosis of ovarian carcinomas
US20040137477A1 (en) * 2002-10-22 2004-07-15 Can-Fite Biopharma, Ltd. A3AR as a marker for a diseased state
US20060263808A1 (en) * 2005-03-25 2006-11-23 Genentech, Inc. C-met mutations in lung cancer
US7615529B2 (en) 2005-03-25 2009-11-10 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921918T2 (de) 1988-05-09 1995-09-07 Univ Temple Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.
JPH04193900A (ja) * 1989-03-31 1992-07-13 Res Dev Found 網膜芽腫遺伝子産物の抗体とその利用
US5234811A (en) * 1991-09-27 1993-08-10 The Scripps Research Institute Assay for a new gaucher disease mutation
EP0631584A4 (de) * 1991-02-28 1998-07-01 Dana Farber Cancer Inst Inc Krebs diagnose und therapie.
AU2178292A (en) * 1991-06-03 1993-01-08 Triton Diagnostics, Inc. Epidermal growth factor receptor ectodomain
CA2096497A1 (en) * 1992-05-26 1993-11-27 Patricia Anne Spears Mycobacteria probes
AU5601194A (en) * 1992-11-13 1994-06-08 California Institute Of Biological Research Identification of neoplasms by detection of genetic insertions and deletions
AU7362294A (en) * 1993-07-15 1995-02-13 Incyte Pharmaceuticals, Inc. Mammalian low molecular weight phospholipase a2 nucleotide and amino acid sequences
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit

Also Published As

Publication number Publication date
EP2014772A3 (de) 2009-05-27
EP0906448B1 (de) 2009-02-25
EP2014772A8 (de) 2009-04-29
DE69739276D1 (de) 2009-04-09
CA2250854C (en) 2011-06-21
EP0906448A4 (de) 2004-12-01
JP2008283985A (ja) 2008-11-27
EP2014772A2 (de) 2009-01-14
JP2000510330A (ja) 2000-08-15
WO1997038125A1 (en) 1997-10-16
AU2438997A (en) 1997-10-29
CA2250854A1 (en) 1997-10-16
EP0906448A1 (de) 1999-04-07

Similar Documents

Publication Publication Date Title
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE386938T1 (de) Ykl-40 als marker und indikator zur prognose von krebs und detektion von infektionen
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
WO2003089897A3 (en) Diagnosis and treatment of vascular disease
ATE198623T1 (de) Verfahren zum nachweis von prädisposition von ovarial- und brustkrebs
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
WO2008084219A8 (en) Epigenetic change in selected genes and cancer
ATE317451T1 (de) Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
DE69739276D1 (de) Methoden zur diagnose und prognose von krebs
WO2003020118A3 (en) Diagnosis and treatment of vascular disease
Wollenberg et al. Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN
DE60036935D1 (de) Diagnostisches Verfahren für Eierstock- und Endometriumtumore basierend auf dem Nachweis des L1-Adhäsionsmoleküls
CN107312867B (zh) 诊断甲状腺功能减退的snp及其应用
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
WO2002053018A3 (en) Method of detecting polymorphisms associated with breast carcinoma in mhc genes
ATE327766T1 (de) Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen
ATE355527T1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
Shen et al. A different method in diagnosis of multiple primary lung cancer
WO2003007801A3 (en) Diagnosis and treatment of vascular disease
ATE442456T1 (de) Verfahren zur bestimmung von zirkulierender dns in plasma und zum nachweis von krebs
DE60309879D1 (de) Verfahren zur Diagnose von Krebs
ATE520031T1 (de) Ibc-1 (invasive breast cancer-1), ein bei brustkrebs amplifiziertes mutmassliches onkogen
ATE474935T1 (de) Verfahren und zusammensetzungen zur bestimmung von mutationen in nukleinsäure und deren verwendung in diagnose von genetischen krankheiten und krebs
EP1438326A4 (de) Diagnose, behandlung und prävention von krebs mit cables

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties